These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 25874001)
1. A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's disease. Nygaard HB; Wagner AF; Bowen GS; Good SP; MacAvoy MG; Strittmatter KA; Kaufman AC; Rosenberg BJ; Sekine-Konno T; Varma P; Chen K; Koleske AJ; Reiman EM; Strittmatter SM; van Dyck CH Alzheimers Res Ther; 2015; 7(1):35. PubMed ID: 25874001 [TBL] [Abstract][Full Text] [Related]
2. Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial. van Dyck CH; Nygaard HB; Chen K; Donohue MC; Raman R; Rissman RA; Brewer JB; Koeppe RA; Chow TW; Rafii MS; Gessert D; Choi J; Turner RS; Kaye JA; Gale SA; Reiman EM; Aisen PS; Strittmatter SM JAMA Neurol; 2019 Oct; 76(10):1219-1229. PubMed ID: 31329216 [TBL] [Abstract][Full Text] [Related]
3. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE). Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896 [TBL] [Abstract][Full Text] [Related]
4. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW; Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA; Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517 [TBL] [Abstract][Full Text] [Related]
6. Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Ringman JM; Frautschy SA; Teng E; Begum AN; Bardens J; Beigi M; Gylys KH; Badmaev V; Heath DD; Apostolova LG; Porter V; Vanek Z; Marshall GA; Hellemann G; Sugar C; Masterman DL; Montine TJ; Cummings JL; Cole GM Alzheimers Res Ther; 2012; 4(5):43. PubMed ID: 23107780 [TBL] [Abstract][Full Text] [Related]
7. A Randomized, Double-Blind, Phase 2 Study of the Effects of the Vaccine Vanutide Cridificar with QS-21 Adjuvant on Immunogenicity, Safety and Amyloid Imaging in Patients with Mild to Moderate Alzheimer's Disease. Ketter N; Liu E; Di J; Honig LS; Lu M; Novak G; Werth J; LePrince Leterme G; Shadman A; Brashear HR J Prev Alzheimers Dis; 2016; 3(4):192-201. PubMed ID: 29199321 [TBL] [Abstract][Full Text] [Related]
8. Fyn inhibition rescues established memory and synapse loss in Alzheimer mice. Kaufman AC; Salazar SV; Haas LT; Yang J; Kostylev MA; Jeng AT; Robinson SA; Gunther EC; van Dyck CH; Nygaard HB; Strittmatter SM Ann Neurol; 2015 Jun; 77(6):953-71. PubMed ID: 25707991 [TBL] [Abstract][Full Text] [Related]
9. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients. Siemers ER; Sundell KL; Carlson C; Case M; Sethuraman G; Liu-Seifert H; Dowsett SA; Pontecorvo MJ; Dean RA; Demattos R Alzheimers Dement; 2016 Feb; 12(2):110-120. PubMed ID: 26238576 [TBL] [Abstract][Full Text] [Related]
13. Fyn kinase inhibition as a novel therapy for Alzheimer's disease. Nygaard HB; van Dyck CH; Strittmatter SM Alzheimers Res Ther; 2014; 6(1):8. PubMed ID: 24495408 [TBL] [Abstract][Full Text] [Related]
14. A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease. Prins ND; Harrison JE; Chu HM; Blackburn K; Alam JJ; Scheltens P; Alzheimers Res Ther; 2021 May; 13(1):106. PubMed ID: 34044875 [TBL] [Abstract][Full Text] [Related]
15. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Chen Z; Zhong C Prog Neurobiol; 2013 Sep; 108():21-43. PubMed ID: 23850509 [TBL] [Abstract][Full Text] [Related]
20. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Doody RS; Gavrilova SI; Sano M; Thomas RG; Aisen PS; Bachurin SO; Seely L; Hung D; Lancet; 2008 Jul; 372(9634):207-15. PubMed ID: 18640457 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]